CARCINOMA, RENAL CELL

This study is testing experimental combinations of immune and targeted drugs for people with advanced kidney cancer that has spread. The research aims to find safe and effective treatment options for 400 participants who haven't received prior treatment for their advanced cancer.…

This study is testing whether a new combination of two drugs (belzutifan plus lenvatinib) works better than an existing drug (cabozantinib) for people with advanced kidney cancer that has continued to grow despite prior immunotherapy. The main goals are to see which treatment hel…

This is an early-stage study to find a safe dose of a new drug called KFA115, given alone or with an existing immunotherapy (pembrolizumab), for people with advanced cancers that have stopped responding to standard treatments. The main goal is to check for side effects and determ…

This study is testing a new targeted drug called savolitinib for people with an advanced form of kidney cancer called MET-driven papillary renal cell carcinoma (PRCC). It compares savolitinib directly against sunitinib, a standard treatment, to see which is better at controlling …

This study is testing whether adding one or two new drugs to the standard treatment works better for advanced kidney cancer. It involves about 249 Chinese patients who haven't had previous treatment for their advanced cancer. Researchers will compare how long patients live withou…

This study aims to learn how the immune system changes when patients with advanced kidney or bladder cancer receive immunotherapy drugs. Researchers will collect blood samples from about 67 patients before and during treatment to measure different immune cells and cancer cells in…